The estimated Net Worth of Michael P. Dillon is at least $4.09 Миллион dollars as of 4 October 2021. Mr. Dillon owns over 1,500 units of IDEAYA Biosciences stock worth over $2,906,462 and over the last 5 years he sold IDYA stock worth over $515,170. In addition, he makes $670,780 as Senior Vice President, Chief Scientific Officer и Head of Research at IDEAYA Biosciences.
Michael has made over 11 trades of the IDEAYA Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of IDYA stock worth $16,620 on 4 October 2021.
The largest trade he's ever made was exercising 11,500 units of IDEAYA Biosciences stock on 7 September 2021 worth over $78,775. On average, Michael trades about 5,404 units every 22 days since 2020. As of 4 October 2021 he still owns at least 80,289 units of IDEAYA Biosciences stock.
You can see the complete history of Mr. Dillon stock trades at the bottom of the page.
Dr. Michael P. Dillon Ph.D. serves as Senior Vice President, Chief Scientific Officer, Head of Research of the Company. Mr. Michael has served in various roles with IDEAYA since April 2016, currently serving as our Senior Vice President and Chief Scientific Officer, Head of Research. From 2008 to 2016, Dr. Dillon was with the Novartis Institutes for Biomedical Research, Inc., a biopharmaceutical company, where he served in various leadership roles, including Global Discovery Chemistry Head, Oncology and New Therapeutic Modalities, Head of Chemical Sciences, Emeryville, and Executive Director for Oncology Chemistry. From 1993 to 2008, Dr. Dillon worked at F. Hoffmann-La Roche Ltd., or Roche, and Syntex Corp. (acquired by Roche), where he served in roles of increasing responsibility, including Director, Medicinal Chemistry. Dr. Dillon obtained his Ph.D. in Chemistry from the University of Bristol and afterward completed his postdoctoral fellowship in Chemistry at Oregon State University. Dr. Dillon obtained his B.S. in Chemistry from the University of Leicester.
As the Senior Vice President, Chief Scientific Officer и Head of Research of IDEAYA Biosciences, the total compensation of Michael Dillon at IDEAYA Biosciences is $670,780. There are 3 executives at IDEAYA Biosciences getting paid more, with Yujiro Hata having the highest compensation of $2,020,990.
Michael Dillon is 53, he's been the Senior Vice President, Chief Scientific Officer и Head of Research of IDEAYA Biosciences since 2017. There are 10 older and 7 younger executives at IDEAYA Biosciences. The oldest executive at IDEAYA Biosciences, Inc. is Wendy Yarno, 65, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at IDEAYA Biosciences have traded over $13,169,580 worth of IDEAYA Biosciences stock and bought 2,220,527 units worth $22,722,236 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Timothy M Shannon и X L.P.Canaan Partners X Llc.... On average, IDEAYA Biosciences executives and independent directors trade stock every 29 days with the average trade being worth of $2,196,906. The most recent stock trade was executed by Jason Throne on 27 June 2024, trading 53,484 units of IDYA stock currently worth $415,571.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences executives and other stock owners filed with the SEC include: